10 years after, Columbia heart surgery study still causing problems Reply

A study that started in 1999 and ended in 2001 is still causing problems for Columbia University Medical Center, according to a detailed investigation by Jeanne Lenzer and Shannon Brownlee in the Huffington Post.

Lenzer and Brownlee report that Columbia has performed three separate internal reviews of the study which “raised serious questions about the drug trial’s design, management and oversight” but found no evidence that patients were harmed and concluded “that there was no need to provide the patients with additional information about the study.”

Now, however, the US Office of Human Research Protections has determined that “at least some of the subjects appear to have suffered harms that were a function of the design and procedures of the study.” OHRP is “demanding that Columbia track down the patients and their families, and acknowledge that they never were informed about the ‘true nature’ of the drug study, the risks they faced or the consequences of their participation.”
Click to continue reading…

Study finds increased use of glucose lowering treatments at the expense of statins and antihypertensives Reply

Physicians have the wrong priorities when treating patients with diabetes, according to a research letter  in the Archives of Internal Medicine.

Mann et al looked at data from diabetics participating in the National Health and Nutrition Examination Survey (NHANES) between 1999 and 2006. During the course of the study period the use of medications to treat glucose, cholesterol, and hypertension increased broadly, although the most impressive changes occurred in glucose control. By the end of the study more than half the patients had HbA(1c) levels lower than 7%, compared to only 43% who had controlled cholesterol and 39% who had controlled hypertension.
Click to continue reading, including a comment from Darren McGuire…

October thought experiment: suppose the World Series were covered like the Nobel Prize Reply

October brings the Nobel Prize announcements and the World Series. No one will mistake media coverage of one for the other. Each Nobel Prize will get one article and 10 seconds on the evening news. A soft feature will quote the new Nobel recipient’s complete surprise at the 4 AM phone call.

By contrast, baseball, like all major sports, is covered in great depth, by legions of sports reporters. Coverage is continuous during the long baseball season, reaches a near-hysterical peak in October, and continues generously even during the off-season.

Let’s try a thought experiment. Imagine for a moment that newspapers covered baseball the way they cover science. What would happen? What kind of articles would we see and what kind of stories would we miss?
Click to continue reading…

Elizabeth Taylor twitters the news she’s about to get an Evalve MitraClip mitral valve 2

Update–October 8: Elizabeth Taylor sent a tweet on Thursday announcing that her procedure had been a success. Here is the tweet: “Dear Friends, My heart procedure went off perfectly. It’s like having a brand new ticker. Thank you for your prayers and good wishes.”

Update–October 7: CardioBrief has heard from a reliable source that Taylor will undergo her procedure today.

Providing proof positive that we live in a world no one could possibly have imagined only a few short years ago, Elizabeth Taylor today twittered the news that she was about to enter the hospital and receive an Evalve MitraClip mitral valve clipping procedure.

CardioBrief has learned that Cedars-Sinai Medical Center is the only hospital in the Los Angeles area that is working with the Evalve device.
Click to continue reading…

9 nontraditional risk factors fail to gain USPSTF recommendations; CRP comes close Reply

Nine nontraditional risk factors have not been shown to improve risk stratification of people at intermediate risk for coronary heart disease, according to three new papers from the US Preventive Services Task Force (USPSTF) appearing in Annals of Internal Medicine. CRP came closest to receiving a recommendation. The authors found “moderate, consistent evidence that adding CRP to risk prediction models among initially intermediate-risk persons improves risk stratification” but did not find sufficient evidence “to assess whether reducing CRP levels prevents CHD events.”
Click to continue reading, including a comment from Sanjay Kaul…

Hypertension in China causes 1.27 million premature deaths a year Reply

Updated with a comment from Franz Messerli– Results of a large prospective cohort study suggest that in 2005 there were approximately 153 million people with hypertension in China, leading to 1.27 million premature deaths from cardiovascular disease. Not surprisingly, the authors argue that “prevention and control of this condition should receive top public-health priority in China.” The results have been published online in the Lancet.
Click to continue reading…

Onglyza (saxagliptin) gains European approval; demonstrates noninferiority to sitagliptin in phase 3b trial Reply

Following FDA approval in the US earlier this year, Onglyza (saxagliptin) received European marketing authorization, according to a press release issued by Bristol-Myers Squibb and AstraZeneca.

According to the companies, Onglyza is indicated as a once-daily 5 mg oral tablet dose in adult patients with type 2 diabetes mellitus to improve glycemic control:
Click to continue reading…

First patient enrolled in study testing duration of antiplatelet therapy after DES Reply

Enrollment is finally underway in the much anticipated Dual Antiplatelet Therapy Study (DAPT), according to an announcement today from the Harvard Clinical Research Institute. DAPT is the product of a unique collaboration that includes the FDA, HCRI, and the following companies, which make stents and the antiplatelet drugs clopidogrel and prasugrel:
Click to continue reading…

Lancet review: will most babies born now live to 100? Reply

If current trends continue, most babies born in this century in developed countries will live to see their 100th birthday, according to an important new review appearing in the Lancet.

A key question is whether the increase in life expectancy will also bring an accompanying delay in functional limitations and disability. There is no clear answer to this question, but Kaare Christensen and coauthors find evidence suggesting that “people are living longer without severe disability.”

According to the authors, the increase in life expectancy shows no sing of deceleration: “The linear increase in record life expectancy for more than 165 years does not suggest a looming limit to human lifespan. If life expectancy were approaching a limit, some deceleration of progress would probably occur. Continued progress in the longest living populations suggests that we are not close to a limit, and further rise in life expectancy seems likely.” However, even if there are no further gains in health and life expectancy, three-fourths of babies born in this century will reach their 75th birthday.
Click to continue reading, including a comment from Harlan Krumholz…

REVERSE at 2 years: CRT may help prevent progression in early HF Reply

Two-year results from the REVERSE trial help support the proposition that cardiac resynchronization therapy may be beneficial in patients with class 1 and 2 heart failure. The results, which were presented initially last March at the American College of Cardiology meeting, have been published online as an expedited paper in the Journal of the American College of Cardiology. The major findings from the trial, the one year results, had been presented a year earlier at the ACC, and failed to demonstrate a benefit for CRT in this population, though trial investigators pointed to signs of reverse ventricular remodeling as an important hint of benefit.
Click to continue reading…

Invitation to Readers: My Mighty Team Reply

Dear CardioBrief Reader,

I am pleased to invite you to become one of the first users of an innovative new website, My Mighty Team, that has just entered beta testing. MIGHTY is a completely free social networking site designed to help people achieve goals such as losing weight, quitting smoking, or exercising more, by using small, focused teams to support and track their progress.
Click to continue reading…

FDA adds pancreatitis warning to Januvia label Reply

The FDA has revised the prescribing information for Januvia (sitagliptin) and Janumet  (sitagliptin/metformin), adding information about reported cases of acute pancreatitis in 88 cases. The FDA recommends that doctors monitor patients  for acute pancreatitis after initiating sitagliptin or increasing the dose.

Merck, which manufactures sitagliptin, released a statement saying it “believes these data do not demonstrate that a causal relationship exists between sitagliptin and pancreatitis.”
Click to read the FDA announcement and the statement from Merck…

Cholesterol prescriptions from Senators Schumer, Grassley, and Nelson 2

It’s only a very small moment within the enormous ongoing debate over health care reform, but a recent exchange in the US Senate over cholesterol remedies highlights the potential pitfalls when politicians talk about medicine.

As reported by David Herzenhorn in the New York Times, New York’s Senator Charles Schumer “said his doctor had directed him to take Lipitor… and then, after his cholesterol levels had dropped, suggested that he try a less expensive, generic medication instead. But he switched back after his cholesterol levels went back up. ‘I’m taking Lipitor even though it’s more expensive.’”
Click to continue reading…

TCT: Ticagrelor again shows benefits in PLATO invasive substudy 4

New results from a subset of the PLATO trial show that ticagrelor was more effective than clopidogrel in preventing events in ACS patients undergoing an invasive strategy.

Under development as Brilinta by AstraZeneca, ticagrelor is an oral, reversible antiplatelet drug with a rapid onset of action. The main results of PLATO in 18,624 ACS patients were presented last month at the ESC and published simultaneously in the New England Journal of Medicine. At TCT today, Chris Cannon presented results of the very large, planned substudy of the 72% of PLATO patients for whom an invasive strategy was intended.

Click to continue reading…

Gregg Stone no longer chairman of Cardiovascular Research Foundation Reply

UpdatedAccording to the website of the Cardiovascular Research Foundation, Gregg Stone is no longer the chairman of CRF. In addition, Stone is identified as the “immediate past chairman” of CRF in the press release for the SPIRIT IV trial issued by Abbott.

As CardioBrief reported yesterday, Stone’s predecessor as chairman, and the founder of the CRF, Martin Leon, was the subject of a letter from Senators Herb Kohl and Charles Grassley regarding potentially undisclosed conflict of interest statements.
Click to continue reading…

TCT: Xience outperforms Taxus in SPIRIT IV, but no difference in diabetics Reply

The Xience V outperformed the Taxus Express 2 in the SPIRIT IV Trial, but didn’t do any better or worse in the highly anticipated subset of diabetic patients. The results were presented at TCT 2009 during the Late Breaking Trials session on Wednesday by Gregg Stone.

At one year, the trial’s primary endpoint– the rate of target lesion failure (TLF)– in the 3,690 patients enrolled in the trial was 4.2% in the Xience V group versus 6.8% in the Taxus group, a highly significant difference. TLF is a combined endpoint of cardiac death, heart attack attributed to the target vessel (target vessel myocardial infarction), and ischemia-driven TLR (ID-TLR).
Click to continue reading…